DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 204078
» See Plans and Pricing
The generic ingredient in BLOXIVERZ is neostigmine methylsulfate. There are nine drug master file entries for this compound. Additional details are available on the neostigmine methylsulfate profile page.
Summary for 204078
Tradename: | BLOXIVERZ |
Applicant: | Exela Pharma |
Ingredient: | neostigmine methylsulfate |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 204078
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 5MG/10ML (0.5MG/ML) | ||||
Approval Date: | May 31, 2013 | TE: | AP | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 10MG/10ML (1MG/ML) | ||||
Approval Date: | May 31, 2013 | TE: | AP | RLD: | Yes |
Complete Access Available with Subscription